Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
17,600
ISIN
US3755581036
Website
Gilead Sciences Metrics
BasicAdvanced
$138B
23.39
$4.73
0.28
$3.12
2.86%
Price and volume
Market cap
$138B
Beta
0.28
52-week high
$119.96
52-week low
$66.01
Average daily volume
8.8M
Dividend rate
$3.12
Financial strength
Current ratio
1.369
Quick ratio
1.061
Long term debt to equity
131.104
Total debt to equity
131.104
Dividend payout ratio (TTM)
66.02%
Interest coverage (TTM)
11.01%
Profitability
EBITDA (TTM)
13,586.75
Gross margin (TTM)
78.29%
Net profit margin (TTM)
20.76%
Operating margin (TTM)
38.11%
Effective tax rate (TTM)
12.60%
Revenue per employee (TTM)
$1,630,000
Management effectiveness
Return on assets (TTM)
12.14%
Return on equity (TTM)
32.66%
Valuation
Price to earnings (TTM)
23.394
Price to revenue (TTM)
4.802
Price to book
7.22
Price to tangible book (TTM)
-16.2
Price to free cash flow (TTM)
14.016
Free cash flow yield (TTM)
7.13%
Free cash flow per share (TTM)
789.57%
Dividend yield (TTM)
2.82%
Forward dividend yield
2.86%
Growth
Revenue change (TTM)
4.68%
Earnings per share change (TTM)
1,118.07%
3-year revenue growth (CAGR)
1.51%
10-year revenue growth (CAGR)
0.45%
3-year earnings per share growth (CAGR)
9.74%
10-year earnings per share growth (CAGR)
-5.99%
3-year dividend per share growth (CAGR)
2.72%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Bulls say / Bears say
The U.S. FDA approved Gilead's twice-yearly HIV prevention injection, lenacapavir, which has demonstrated near 100% effectiveness in clinical trials, potentially expanding the company's market share in HIV treatments. (reuters.com)
Gilead reported a 6% increase in fourth-quarter revenue to $7.57 billion, surpassing Wall Street's projection of $7.14 billion, indicating strong financial performance. (reuters.com)
The company's flagship HIV drug, Biktarvy, saw a 7% sales increase to $3.15 billion in the first quarter of 2025, reflecting sustained demand and market dominance. (reuters.com)
The U.S. FDA placed a clinical hold on Gilead's trials testing a combination of experimental HIV drugs due to participants developing low levels of CD4+ T-cells, potentially delaying product development. (reuters.com)
Gilead's oncology drug Trodelvy experienced a 5% drop in sales to $293 million in the first quarter of 2025, attributed to pricing and inventory issues, indicating challenges in the oncology segment. (reuters.com)
The company anticipates a $900 million reduction in HIV sales revenue in 2025 due to Medicare reforms, which could impact overall financial performance. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Jun 2025.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
GlobeNewsWire·2 days ago
Gilead shares rise after US top court ruling on preventative coverage
Reuters·3 days ago
Gilead partners with Kymera to develop novel cancer therapy
Proactive Investors·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $138B as of June 30, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 23.39 as of June 30, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of June 30, 2025, the dividend rate is $3.12 and the yield is 2.86%. Gilead Sciences has a payout ratio of 66.02% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment date is unconfirmed.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.